Opioid Use Disorder Treatment Market By Treatment Type (Medication {Methadone, Buprenorphine, Naltrexone, Naloxone}, Behavioral Therapies {Cognitive Behavioral Therapy, Motivational Interviewing}), Rehabilitation and Detoxification, Alternative Therapies), By Application (Pain Management, Addiction Management, Overdose Reversal), By Route of Administration (Oral, Sublingual, Intramuscular, Subcutaneous, Intranasal), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics), and By End-user (Hospitals, Rehabilitation Centers, Clinics, Homecare), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Opioid Use Disorder Treatment market accounted for USD 5.16 Billion in 2024 and is expected to reach USD 14.36 Billion by 2035, growing at a CAGR of around 9.75% between 2025 and 2035. The opioid use disorder treatment market is defined as the industry that offers solutions for patients who have opioid addiction. Types of treatment include medication-assisted treatments (MAT), behavioral therapies, rehabilitation, and detoxification services. This market has emerged in response to the global opioid crisis, driven by the need for therapies to manage opioid dependence, prevent overdose, and support patients in recovery.

Opioid treatment means and covers products for treating opioid dependency, including pharmaceutical products, medical services, and healthcare structures for these purposes. As the demand for extensive addiction treatment increases, the market for OUD treatment also grows.

Report Scope:

Market Dynamics

Surging Opioid Addiction Cases Propel Demand for Advanced Treatment Solutions

Pharmacy regulations, politics, legislation, and the opioid epidemic continue to drive advancements in the Opioid Use Disorder (OUD) treatment market. With opioid misuse still on the rise in the whole world, more and more patients still need efficient, research-based treatments for opioid use disorders, overdose risk reduction, and recovery. Due to the opioid crisis in countries like America, awareness has been created regarding other ways by which addiction can be treated, like rehabilitation and counseling together with medication-assisted treatment, or commonly known as MAT. Relying on CDC data, overdose deaths from opioids in the United States in 2020 reached slightly more than 81 thousand. Therefore, we need effective treatments. This has set up the pace of upcoming innovations in treatment offerings and also the growth of healthcare services to manage conditions related to OUD. Governments and healthcare systems are funding and developing programs for advanced therapies aimed at treating Opioid Use Disorder (OUD), contributing to the growth of this market.

Innovative Therapies Revolutionize Opioid Use Disorder Treatment Landscape

New treatment modalities are quickly transforming the treatment of Opioid Use Disorder since they present enhanced and tailored approaches to address opioid dependency. The introduction of long-acting formulations, such as extended-release buprenorphine injections and non-opioid alternatives, has improved patient compliance and reduced the likelihood of sporadic relapses, thereby enhancing treatment success rates.

Furthermore, the use of devices in health and telemedicine solution delivery systems is enhancing the reach and availability of care to underserved areas and populations, making it easier for individuals to access treatment. Medical firms have sunk capital into innovative research to discover new drugs that can interact with opioid receptors with little or no side effects, which will help to make the sometimes unpleasant experience of seeking medication a much more pleasant one. Such improvements are promoting adaptive treatments for OUD, driven by government policies and partnerships, to help meet the growing demand for responsive and non-judgmental healthcare solutions.

Social Stigma Hinders Access to Opioid Use Disorder Treatment

Pride or prejudice from other community members is among the biggest challenges currently facing the Opioid Use Disorder (OUD) treatment market. Multiple stigmatized barriers are present in OUD patients, such as shame and resulting reluctance to seek care. This stigma exists not only in the wider population but also within the healthcare setting. Eliminating biases against individuals with addiction is essential to ensure they receive adequate care. The view that the disease is not an actual sickness but rather an act of volition also hinders treatment outcomes.

Such barriers hinder the accomplishment of the intended goals of public health interventions and lower the efficiency of government-funded programs. Efforts toward demystifying the perception of stigma as well as the adoption of educational, advocacy, and supportive policies and practices would go a long way in enhancing the number of patients with OUD benefiting from the life-saving treatment.

Non-Addictive Alternatives Pave the Way for Safer Pain Management Solutions

There is still a huge opportunity for development in the OUD treatment market due to non-addictive therapies for patients with chronic pain. New drugs with less tendency to morphine-type activity, but which act selectively on various channels or pathways in the nervous system, are becoming popular. These drugs appear to give effective analgesia without producing addiction. Signs of hope, defined by innovations in implantable neurostimulation devices and non-invasive treatment methodologies, are significant forces driving change in pain management. These alternatives are not only necessary for avoiding opioid abuse but also for helping patients in recovery from addiction, who need pain management services. Higher investment in non-addictive treatment options and government incentives to support safer treatments explain the growth in this segment as a leading opportunity in the OUD treatment market.

Rising R&D Investments Drive Innovation in Safer, More Effective Opioid Treatments

An increase in R&D spending acts as a driver in the OUD treatment market and the improvement of safer opioid therapies. Critically ill Chronic pain management, wellness, and diseases are key areas where pharmaceutical companies and healthcare organizations are making significant investments for future medical assistance, including next-generation formulations such as long-acting treatments, non-opioid medications, and personalized medicine. Such investments are intended to alleviate commonly associated issues with existing therapies such as side effects, compliance issues, and relapse.

Increased government and private support are also invigorating clinical trials and the clearance of new therapeutic options. Not only is the organ-on-a-chip technology shifting existing drug discovery from a trial-and-error process to highly effective targeted drugs made possible by modern biotechnology and AI. Only by accelerating the development of new interventions, which is now possible due to the identified increase in R&D activity, can we improve patient outcomes and reduce addiction rates to change the course of OUD treatment in the future.

Industry Experts Opinion

"When people are ready to seek OUD treatment, there should be no financial hurdles preventing them from receiving care." 

• Dr. Arthur Robin Williams, Chief Medical Officer, Ophelia

"We need more insurers to offer coverage for effective opioid addiction treatment, and we need them to do so now. It's the right thing to do, and it's smart business-while OUD is expensive for the healthcare system, it's even more expensive if it continues to go untreated."

• Zack Gray, CEO and co-founder at Ophelia

Segment Analysis

Based on the treatment type, the opioid use disorder treatment market has been classified into Medication, Behavioral Therapies, Rehabilitation and Detoxification, and Alternative Therapies. The medication segment is the largest type of treatment for the Opioid Use Disorder (OUD) treatment market. Medication-assisted treatment (MAT) is well known by multidisciplinary teams and patients in general as a highly effective method for treating OUD with the use of a pharmaceutically assisted approach, including methadone, buprenorphine, and naltrexone alongside psychosocial interventions.

The MAT also reduces opioid cravings and withdrawal symptoms, and for this reason, it is the recommended form of treatment. Due to their effectiveness in refining the treatment experience for patient consumers and their enhanced availability, these meds have become popular. This segment remains the most prominent category because of its long history in OUD management and increasing demand for effective and affordable treatments.

Based on the application, the opioid use disorder treatment market has been classified into Pain Management, Addiction Management, and Overdose Reversal. The addiction management segment is also the largest in the Opioid Use Disorder (OUD) treatment industry. This segment is concerned with the solution-based treatment of the disorder, including the use of medicines such as methadone, buprenorphine, and naltrexone, besides correcting maladaptive behaviors.

Due to the rise of opioid use, addiction treatment has turned into a significant part of treatment systems, which makes this segment a key factor for the OUD treatment market. The development of addiction treatment facilities, combined with favorable government policies, enhances their influence on market dominance.

Regional Analysis

The North American region is the largest opioid use disorder treatment market on account of high opioid addiction populations in the United States and Canada. There are different types of treatment available for different patients in the region, including medication-assisted treatment (MAT), counseling, and other rehabilitation services. The opioid-related crisis has also given a boost to this market through government funding and initiatives to control the problem.

Further, the growth of knowledge in addiction treatment and the growing number of healthcare centers focused on OUD treatment are the factors driving the market's growth. The market is also fortunate to have prominent stakeholders within the North American healthcare sector who are constantly developing new therapies to meet the ever-increasing need for OUD treatments. Moreover, an increasing number of suppliers, including those offering telemedicine and digital health tools for addiction treatment, are expected to influence market development in the future.

The Asia Pacific region has been identified as having the fastest-growing opioid use disorder treatment market therapies due to increasing cases of dependency on opioids across the world, in particular in India, China, and Australia. Stimulated by the growing rate of population density in the region, opioid access and abuse must have manageable methods of treatment. Governments in the Asia-Pacific region are finalizing measures to curb opioid vice, developing policies regarding better treatment of addiction disorders, and involving medication-assisted therapies and rehabilitation.

An increased social acceptance of addiction and mental disorders, together with a focus on differentiation in the treatment industry, is also driving the need for these services. In the same respect, the continued growth of healthcare facilities and increased accessibility to treatment of OUD by global pharmaceutical players is also fueling the growth of the market. As investments in addiction care continue and more people embrace telemedicine and digital health solutions, the region is poised for steady growth in the OUD treatment market.

Competitive Landscape

Major players are developing attractive therapies for opioid use disorder (OUD) treatment to remain competitive in the market. Key companies in this field include Indivior PLC, Orexo AB, Pfizer Inc., and Novartis AG. Nonetheless, there is still the domination of Indivior and Suboxone through the provision of better, faster, and cheaper treatment, and Orexo has also obtained an improved market status, such as Zubsolv. New events include the company’s partnership with various organizations about the opioid epidemic through treatment and governments.

However, there has been progress in the development of new opioid treatments by Cerevel Therapeutics and Camurus AB. Businesses are increasingly focusing on developing innovative formulations, non-opioid alternatives, and personalized strategies to enhance patient well-being. These treatments, combined with increased investments in research and development to discover new methods for treating OUD, are defining the future of OUD treatment.

Opioid Use Disorder Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In May 2023, the U.S. FDA approved Brixadi (buprenorphine) extended-release injection for subcutaneous administration as a treatment for opioid use disorder (OUD).
• In April 2023, the New York State Department of Health (DOH) and the New York State Office of Addiction Services and Supports (OASAS) introduced the Buprenorphine Assistance Pilot Program to help cover the cost of buprenorphine for OUD treatment.

Report Coverage:

By Treatment Type

• Medication
  • Methadone
  • Buprenorphine
  • Naltrexone
  • Naloxone
• Behavioral Therapies
  • Cognitive Behavioral Therapy (CBT)
  • Motivational Interviewing (MI)
• Rehabilitation and Detoxification
• Alternative Therapies

By Application

• Pain Management
• Addiction Management
• Overdose Reversal

By Route of Administration

• Oral
• Sublingual
• Intramuscular
• Subcutaneous
• Intranasal

By Distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics

By End-user

• Hospitals
• Rehabilitation Centers
• Clinics
• Homecare

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Indivior PLC
• Orexo AB
• Pfizer Inc.
• Novartis AG
• West Pharmaceutical Services, Inc.
• Astellas Pharma Global Development, Inc.
• AstraZeneca Pharmaceuticals
• BiocorRx, Inc.
• Cerevel Therapeutics, LLC
• Adynxx, Inc.
• Artys Biotech, LLC
• Astraea Therapeutics, LLC
• Delpor, Inc.
• Kinoxis Therapeutics
• Camurus AB

Frequently Asked Questions (FAQs)